CellFE CAR T Cell Editing
Gated Content Access Form - App Note
In the rapidly evolving field of cellular engineering, achieving complex gene edits with high efficiency and minimal workflow disruption remains a significant challenge. CellFE has developed a novel hybrid workflow combined with the use of Syenex virus that leverages the strengths of nonviral gene editing and viral transduction to overcome these challenges. This approach leverages CellFE’s delivery technology to complement Syenex’s next-generation T cell vector system (“SNX-T1”). The integrated approach couples nonviral knockout (KO) with viral knockin (KI) to create a highly efficient, single-day workflow for complex gene editing..
Please fill out the form below to view the PDF.
Recent Articles
CellFE’s platform enables efficient multiplex CRISPR-Cas9 editing to engineer T cells
Managing toxicity and specificity of cell therapies relies on complex gene-editing mechanisms, requiring co-delivery of multiple gene-editing molecules.
CellFE Announces Launch of First-in-Class T-Rest (“Resting T Cell Kit”) for Breakthrough CAR-T Cell Therapy Manufacturing
CellFE® today announced the launch of its highly anticipated CellFE T-Rest™, a first-in-class cell manufacturing transfection media product designed specifically for resting T cell workflows, along with an app note.
Endpoints News: CellFE raises $22M Series A to advance a new cell therapy manufacturing idea
Exclusive: The California-based startup CellFE has raised a $22 million Series A to advance a new approach to making cell therapies with microfluidics.